索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]黄磊 丛欣 幺天保 解玉泉.心原性恶病质的药物治疗进展[J].国际心血管病杂志,2020,01:23-28.
点击复制

心原性恶病质的药物治疗进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2020年01期
页码:
23-28
栏目:
综述
出版日期:
2020-01-14

文章信息/Info

Title:
-
作者:
黄磊 丛欣 幺天保 解玉泉
315336宁波市杭州湾医院心内科(黄磊,丛欣); 200127上海交通大学医学院附属仁济医院心内科(幺天保,解玉泉)
Author(s):
-
关键词:
心力衰竭;  心原性恶病质;  病理生理机制;  药物治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2020.01.006
文献标识码:
-
摘要:
心原性恶病质是不同病因导致的慢性心力衰竭晚期的一种严重并发症,伴随患者进行性体质量下降,骨骼肌和脂肪组织减少。心原性恶病质的发病机制复杂,主要机制有神经激素激活、免疫和炎性反应激活、代谢失衡及胃肠功能改变等。目前尚无关于心原性恶病质预防及治疗的临床指南,根据其病理生理机制进行相应的药物治疗为临床提供了可行的方案。该文介绍心原性恶病质的药物治疗进展。
Abstract:
-

参考文献/References

[ 1 ]Graul AI, Stringer M, Sorbera L. Cachexia[J]. Drugs Today(Barc), 2016, 52(9):519-529.
[ 2 ]Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J]. Eur J Heart Fail, 2016, 18(8):891-975.
[ 3 ]Okoshi MP, Capalbo RV, Romeiro FG, et al. Cardiac cachexia: perspectives for prevention and treatment[J]. Arq Bras Cardiol, 2017, 108(1):74-80.
[ 4 ]Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure[J]. Eur Heart J, 1999, 20(9):683-693.
[ 5 ]Florea VG, Henein MY, Rauchhaus M, et al. The cardiac component of cardiac cachexia[J]. Am Heart J, 2002, 144(1):45-50.
[ 6 ]Okoshi MP, Romeiro FG, Paiva SA, et al. Heart failure-induced cachexia[J]. Arq Bras Cardiol, 2013, 100(5):476-482.
[ 7 ]Rolfe M, Kamel A, Ahmed MM, et al. Pharmacological management of cardiac cachexia: a review of potential therapy options[J]. Heart Fail Rev, 2019, 24(5):617-623.
[ 8 ]Hryniewicz K, Androne AS, Hudaihed A, et al. Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure[J]. J Card Fail, 2003, 9(6):464-468.
[ 9 ]Yoshida T, Tabony AM, Galvez S, et al. Molecular mechanisms and signaling pathways of angiotensin Ⅱ-induced muscle wasting: potential therapeutic targets for cardiac cachexia[J]. Int J Biochem Cell Biol, 2013, 45(10):2322-2332.
[10]Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study[J]. Lancet, 2003, 361(9363):1077-1083.
[11]Marzetti E, Calvani R, Dupree J, et al. Late-life enalapril administration induces nitric oxide-dependent and independent metabolic adaptations in the rat skeletal muscle[J]. Age(Dordr), 2013, 35(4):1061-1075.
[12]Scherrer-Crosbie M. Losartan: a new treatment for cardiac cachexia?[J]. J Mol Cell Cardiol, 2015, 86:12-13.
[13]Springer J, Filippatos G, Akashi YJ, et al. Prognosis and therapy approaches of cardiac cachexia[J]. Curr Opin Cardiol, 2006, 21(3):229-233.
[14]Anker SD, Von Haehling S. Inflammatory mediators in chronic heart failure: an overview[J]. Heart, 2004, 90(4):464-470.
[15]Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective[J]. Respir Res, 2001, 2(5):269-272.
[16]Mann DL, Mcmurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation(RENEWAL)[J]. Circulation, 2004, 109(13):1594-1602.
[17]Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure(ATTACH)trial[J]. Circulation, 2003, 107(25):3133-3140.
[18]Von Haehling S, Lainscak M, Springer J, et al. Cardiac cachexia: a systematic overview[J]. Pharmacol Ther, 2009, 121(3):227-252.
[19]Sliwa K, Skudicky D, Candy G, et al. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy[J]. Lancet, 1998, 351(9109):1091-1093.
[20]Steffen BT, Lees SJ, Booth FW. Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia[J]. J Appl Physiol, 2008, 105(6):1950-1958.
[21]Shaw SM, Shah MK, Williams SG, et al. Immunological mechanisms of pentoxifylline in chronic heart failure[J]. Eur J Heart Fail, 2009, 11(2):113-118.
[22]Loncar G, Springer J, Anker M, et al. Cardiac cachexia: hic et nunc: "hic et nunc"—here and now[J]. Int J Cardiol, 2015, 201:e1-e12.
[23]Colldén G, Tschöp MH, Müller TD. Therapeutic potential of targeting the ghrelin pathway[J]. Int J Mol Sci, 2017, 18(4):E798.
[24]Isgaard J, Bergh CH, Caidahl K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure[J]. Eur Heart J, 1998, 19(11):1704-1711.
[25]Von Haehling S, Ebner N, Dos Santos MR, et al. Muscle wasting and cachexia in heart failure: mechanisms and therapies[J]. Nat Rev Cardiol, 2017, 14(6):323-341.
[26]Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure[J]. Circulation, 2001, 104(12):1430-1435.
[27]Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure[J]. Circulation, 2004, 110(24):3674-3679.
[28]Nagaya N, Kangawa K. Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failure[J]. Curr Opin Pharmacol, 2003, 3(2):146-151.
[29]Goodale T, Sadhu A, Petak S, et al. Testosterone and the heart[J]. Methodist Debakey Cardiovasc J, 2017, 13(2):68-72.
[30]Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial[J]. Eur Heart J, 2006, 27(1):57-64.
[31]Toma M, Mcalister FA, Coglianese EE, et al. Testosterone supplementation in heart failure: a meta-analysis[J]. Circ Heart Fail, 2012, 5(3):315-321.
[32]Von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments[J]. J Am Med Dir Assoc, 2014, 15(12):866-872.
[33]Sundaram V, Fang JC. Gastrointestinal and liver issues in heart failure[J]. Circulation, 2016, 133(17):1696-1703.
[34]Valentova M, Von Haehling S, Bauditz J, et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure[J]. Eur Heart J, 2016, 37(21):1684-1691.
[35]Sandek A, Swidsinski A, Schroedl W, et al. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia[J]. J Am Coll Cardiol, 2014, 64(11):1092-1102.
[36]Kitai T, Tang WHW. Gut microbiota in cardiovascular disease and heart failure[J]. Clin Sci(Lond), 2018, 132(1):85-91.
[37]Azhar G, Wei JY. New approaches to treating cardiac cachexia in the older patient[J]. Curr Cardiovasc Risk Rep, 2013, 7(6):480-484.
[38]Cui X, Ye L, Li J, et al. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients[J]. Sci Rep, 2018, 8(1):635.
[39]Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis[J]. J Am Coll Cardiol, 2014, 64(18):1908-1914.
[40]Karpov RS, Dudko VA, Shipulin VM, et al. The clinical instrumental evaluation of treatment efficacy in patients with concomitant atherosclerosis of the coronary, cerebral and peripheral arteries[J]. Ter Arkh, 1991, 63(4):90-93.
[41]Vilskersts R, Liepinsh E, Mateuszuk L, et al. Mildronate, a regulator of energy metabolism, reduces atherosclerosis in apoE/LDLR-/- mice[J]. Pharmacology, 2009, 83(5):287-293.
[42]Nedoshivin AO, Petrova NN, Kutuzova AE, et al. Effect of mildronate on life quality of patients with chronic heart failure[J]. Ter Arkh, 1999, 71(8):10-12.
[43]Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease[J]. Circ Res, 2017, 120(7):1183-1196.
[44]Cheng M, Gao T, Xi F, et al. Dexmedetomidine ameliorates muscle wasting and attenuates the alteration of hypothalamic neuropeptides and inflammation in endotoxemic rats[J]. PLoS One, 2017, 12(3):e0174894.
[45]Dutt V, Gupta S, Dabur R, et al. Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action[J]. Pharmacol Res, 2015, 99:86-100.
[46]Lima AR, Martinez PF, Okoshi K, et al. Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure[J]. Int J Exp Pathol, 2010, 91(1):54-62.

备注/Memo

备注/Memo:
作者单位:315336宁波市杭州湾医院心内科(黄磊,丛欣); 200127上海交通大学医学院附属仁济医院心内科(幺天保,解玉泉)
通信作者:解玉泉,E-mail:xyqah@163.com
更新日期/Last Update: 2020-01-15